Welcome to our dedicated page for Merit Med Sys SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Merit Medical Systems, Inc. (NASDAQ: MMSI) provide detailed information on the company’s financial condition, operations, risk factors, and material events as a Utah‑incorporated medical device and healthcare technology company. Through Forms 10‑K and 10‑Q, investors can review net sales by segment, gross profit, operating expenses, and other key metrics for Merit’s Cardiovascular and Endoscopy businesses, along with discussions of risks related to regulation, reimbursement, supply chain, acquisitions, and market conditions.
Merit also uses Form 8‑K to report significant developments. Recent 8‑K filings have furnished press releases on quarterly and preliminary revenue results, financial guidance, and non‑GAAP measures such as constant currency revenue, non‑GAAP operating margin, non‑GAAP net income, and non‑GAAP earnings per share. Other 8‑Ks disclose leadership and board changes, including the appointment of a new President and Chief Executive Officer and related compensation arrangements, as well as transitions in board roles.
Additional 8‑K filings document acquisition activity and product updates. Merit has reported signing and closing an asset purchase agreement to acquire the C2 CryoBalloon device and related technology, including the proposed purchase consideration and the expected impact on revenue and earnings measures. The company has also furnished press releases on updates to its WRAPSODY Cell‑Impermeable Endoprosthesis product, including commercialization and reimbursement developments.
On this page, Stock Titan presents Merit’s SEC filings with real‑time updates from EDGAR and AI‑powered summaries that explain the context and key points of each document. Investors can quickly scan annual reports (Form 10‑K), quarterly reports (Form 10‑Q), and current reports (Form 8‑K) to understand segment performance, non‑GAAP reconciliations, acquisition terms, leadership changes, and risk disclosures. Filings related to executive appointments and compensation, as well as transaction‑related disclosures, help users analyze governance and incentive structures alongside the company’s operating and financial trends.
Merit Medical Systems has completed a planned leadership transition, appointing Martha G. Aronson as President and Chief Executive Officer effective October 3, 2025. The Board also expanded from ten to eleven members and named her to the Board, while longtime leader Fred P. Lampropoulos moves from President and CEO to Executive Chairman through January 3, 2026 and will remain Board Chair thereafter.
Aronson’s employment terms include a $1,000,000 annual base salary, a $250,000 signing bonus, eligibility for an annual bonus targeting 100% of salary (up to 200%), and participation in the long-term equity plan with an expected initial equity award valued at $5,500,000 plus an additional $4,125,000 in performance and restricted stock units. She will also receive a $12,000 monthly transition allowance through September 30, 2026 and relocation and legal fee reimbursements. Lampropoulos retains his existing compensation through the transition period, and a separate consulting agreement with additional compensation is under negotiation.
Martha Goldberg Aronson, President and CEO and a director of Merit Medical Systems, Inc. (MMSI), reported an amended Form 4 showing a grant of 19,594 restricted stock units (RSUs) on
MERIT MEDICAL SYSTEMS INC filed an amended Form 3 for insider Martha Goldberg Aronson, who serves as President, CEO, and director. This amendment is an updated initial statement of her beneficial ownership in company securities and, based on the data provided, shows no reported transactions or share movements.
Martha Goldberg Aronson, President and CEO of Merit Medical Systems, Inc. (MMSI), received a grant of 19,594 restricted stock units (RSUs) on
Aronson Martha Goldberg filed an Initial Statement of Beneficial Ownership (Form 3) for Merit Medical Systems Inc. The filing lists her address in South Jordan, UT and identifies her role as President and CEO. The date of the event requiring the statement is
The filing discloses no securities beneficially owned by the reporting person at the time of this Form 3. The document was signed by an attorney-in-fact, Brian G. Lloyd, on
Merit Medical Systems insider transactions: The company's President and CEO, Fred P. Lampropoulos, reported multiple stock option exercises and share surrenders on 08/29/2025. He exercised 159,151 options at a $55.73 exercise price and an additional 2,000 options at $55.73, resulting in 159,151 and 2,000 underlying shares respectively that were reported as acquired. He also surrendered 124,824 shares (for payroll taxes and option payment) and his spouse surrendered 1,454 shares for the same purpose; neither surrender involved open-market sales. Post-transactions, Mr. Lampropoulos beneficially owned 1,204,779 shares directly and certain additional shares indirectly through spouse and 401(k) holdings. Several outstanding option grants with various exercise prices and vesting schedules remain.
Lynne N. Ward, a director of Merit Medical Systems, Inc. (MMSI), executed option exercises and share sales on 08/22/2025. She exercised 3,000 non-qualified stock options with a $34.46 exercise price, resulting in 3,000 shares acquired. The same day she sold 3,000 shares in multiple transactions at a weighted average price of $88.56. After these transactions she beneficially owned 12,809 shares. The exercised options were originally granted with a $34.46 strike and become exercisable in equal annual installments of 33% commencing 08/28/2020; the exercised tranche had an expiration date of 08/28/2026.
Merit Medical Systems, Inc. (MMSI) Form 144 notice reports a proposed sale of 3,000 common shares valued at $265,683 to be sold through Morgan Stanley Smith Barney on NASDAQ on 08/22/2025. The filing states these shares were acquired the same day via stock option exercise and paid for in cash. The filer represents no undisclosed material adverse information about the issuer. The filing also lists a prior sale by Lynne Ward of 2,433 shares on 08/11/2025 for $206,535.91. Outstanding shares are listed as 59,219,117.
Lynne N. Ward, a director of Merit Medical Systems (MMSI), reported transactions dated 08/11/2025 on a Form 4. The filing shows the exercise of non-qualified stock options with an exercise price of $34.46 and an associated acquisition of 2,433 shares, and a contemporaneous sale of 2,433 shares at $84.8894.
Following the reported activity the form lists non-derivative beneficial ownership figures of 15,242 and 12,809 shares (as reported on separate lines) and indicates 3,000 derivative securities beneficially owned after the transactions, with 5,433 underlying common shares referenced for the options. The form is signed by an attorney-in-fact on 08/12/2025.
Merit Medical Systems (MMSI) submitted a Form 144 reporting a proposed sale of 2,433 common shares, with an aggregate market value of $206,535.91. The shares are listed on NASDAQ and the filing shows 59,219,117 shares outstanding for the issuer, indicating the position sold is a very small fraction of the company’s total shares. The securities were acquired and are being sold on 08/11/2025 as a result of a stock option exercise, and payment was in cash. The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, New York.
The filing indicates Nothing to Report for securities sold in the past three months. The provided content does not identify the named seller or filer CIK in the visible text. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.